Developer of therapeutics intended for mood disorders. The company targets the important intersection between pain and opioid use disorder and its product is under evaluation for the treatment of subsets of depression through a unique mechanism of action, providing medical practitioners with a potentially safer and more widely available alternative for both pain management and opioid maintenance therapy.
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
2. Merger/Acquisition | 09-Jul-2020 | 00.000 | Completed | Generating Revenue | ||
1. Early Stage VC (Series A1) | 28-Aug-2019 | 00.000 | 00.000 | 00.000 | Completed | Stealth |
Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A-1 | 00,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00 |
Series A-2 | 10,800,000 | $0.000100 | 8% | $0.42 | $0.42 | 1x | $0.42 | 0% |
Name | Title | Board Seat | Contact Info |
---|---|---|---|
Srinivas Rao Ph.D | Chief Executive Officer | ||
Andrew Kruegel Ph.D | Co-Founder, President & CSO |